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Abstract:
While estrogens have been shown to modulate EGFR/HER-1 and HER-2/neu expression in experimental systems, the effects of estrogen deprivation on expression levels of the HER-receptors and the neuregulin (NRG)1 ligand in breast cancers remain unknown. Here, we measured EGFR/HER-1-4 and NRG1 mRNA in ER positive tumors from 85 postmenopausal breast cancer patients before and after two weeks (n=64) and three months (n=85) of primary treatment with an aromatase inhibitor (AI). In tumors lacking HER-2/neu amplification, quantitative real-time PCR analyses revealed EGFR/HER-1 and NRG1 to vary significantly between the three time points (before therapy, after 2 weeks and after 3 months on treatment; P ≤ 0.001 for both). Pair-wise comparison revealed a significant increase in EGFR/HER-1 already during the first two weeks of treatment (P = 0.049) with a further increase for both EGFR/HER-1 and NRG1 after 3 months on treatment (P ≤ 0.001 and P = 0.001 for both comparing values at 3 months to values at baseline and 2 weeks respectively). No difference between tumors responding versus non-responders was recorded. Further, no significant change in any parameter was observed among HER-2/neu amplified tumors. Analyzing components of the HER-2/neu PI3K/Akt downstream pathway, the PI3CA H1047R mutation was associated with treatment response (P = 0.035); however no association between either AKT phosphorylation status or PI3CA gene mutations and EGFR/HER-1 or NRG1 expression levels were observed. Our results indicate primary AI treatment to modulate expression of HER-family members and the growth factor NRG1 in HER-2/neu non-amplified breast cancers in vivo. Potential implications to long term sensitivity warrants further investigations. 
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1. Introduction: 
Estrogen deprivation with aromatase inhibitors (AIs) represents the standard endocrine treatment for postmenopausal breast cancer patients []. However, following or sometimes even during adjuvant AI therapy, patients may experience relapsing disease and, in the metastatic setting resistance to AI-therapy inevitably occurs []. Thus, elucidating the molecular changes in the tumors during endocrine manipulation is important for understanding the mechanisms of endocrine resistance [].
Around 10 % of ER positive breast cancers overexpress the human epidermal growth factor receptor 2 (HER-2/neu)  ADDIN EN.CITE [], and high expression of HER-2/neu is associated with an inferior response to endocrine therapy in tumors expressing the ER and HER-2/neu receptors in concert  ADDIN EN.CITE []. Several in vitro studies using long-term estrogen deprived (LTED) breast cancer cells and MCF-7 cells with acquired resistance to AIs demonstrate adaptive changes leading to activation of alternate signaling pathways and increased expression of e.g. EGFR/HER-1, HER-2 and Insulin-like Growth Factor 1 Receptor (IGF-IR)  ADDIN EN.CITE []. This has also been confirmed in xenograft models where adaption of the cells to low estrogen levels is accompanied by up-regulation of HER-2/neu and downregulation of ER and aromatase activity  ADDIN EN.CITE [, ]. Thus, increased expression or activation of growth factor receptors and cross-talk between ER- and alternate growth factor signaling pathways may cause endocrine resistance  ADDIN EN.CITE []. 
In addition to HER-2/neu, three HER-receptor tyrosine kinase family contains EGFR/HER-1, HER-3 and HER-4. These receptors are activated by ligand binding, leading to formation of either homo- or heterodimers with activation of the intrinsic receptor kinase activity and its downstream targets  ADDIN EN.CITE [, ]. HER-2/neu has no known ligand, but is the preferred dimerization partner for the other HER receptors  ADDIN EN.CITE []. The HER-2/neu : HER-3 heterodimer is recognized as a particular potent stimulator of tumor cell proliferation  ADDIN EN.CITE []. HER-3 is activated by neuregulins (NRGs) such as NRG1. Because HER-3 has no intrinsic kinase activity it depends on heteromeric binding, with a preference for HER-2/neu, to execute its activity.
Combining endocrine therapy with targeted therapy against growth factors has been shown to be superior to AI treatment alone in subsets of ER positive breast cancers  ADDIN EN.CITE [, ], but our understanding of the regulation of HER-receptor expression in breast tumors during endocrine treatment remains poor. In the present study, we determined EGFR/HER-1, HER-2/neu, HER-3, HER-4 and NRG1 mRNA expression levels in ER positive tumors before and during treatment with AIs. The primary aim was to explore changes in gene expression as an effect of treatment, a secondary aim was to study components of a downstream signaling pathway of the HER-receptors where PI3CA gene mutations and pAKT protein levels were analyzed in a subset of tumors and associated with treatment response and HER-gene expression levels. 


2. Material and Methods:
2.1. Study population
The present material was collected from three similar protocols performed in Bergen, Norway (B), and Edinburgh, UK (E) as previously reported  ADDIN EN.CITE []. In summary, a total of 85 postmenopausal breast cancer patients treated with a nonsteroidal AI (anastrozole or letrozole) as primary medical treatment were enrolled, 64 from Edinburgh, and 21 from Bergen (Table 1). All patients provided written informed consent, and each protocol was approved by the local regulatory authorities. All patients had ER positive tumors, however two tumors were found to be ER negative after reanalysis. In the largest study (E, n=64, letrozole), 48 patients had HER-2/neu non-amplified disease, eight were amplified for HER-2/neu and another eight patients had unknown HER-2/neu status. In the two other protocols (B, n=21), patients were treated either with letrozole (n=12) or anastrozole (n=9). Twenty of the patients had HER-2/neu non-amplified disease, whereas one tumor was amplified for HER-2/neu. 

Table 1. Patient and tumor characterizations
Parameters		Number of patients Edinburgh (E)	Number of patients Bergen (B)
Total		64	21
ER status	PositiveNegativea	631	201
HER-2/neu status	AmplifiedNon-amplifiedUnknownb	8488	120-
Treatment 	LetrozoleAnastrozole	64-	129
Response	RespondersNon-respondersUnclassifiedc	351514	174-







a Two tumors were considered ER negative after reanalysis
b Patients were recruited before HER-2/neu became routinely assessed in the clinic
c Inconsistencies in clinical response assessments
ER; estrogen receptor, HER-2/neu; human epidermal growth factor receptor 2



2.2. Treatment and tissue collection
Nine patients received anastrozole at an oral dose of 1 mg daily for 15 weeks (B). Letrozole was given as an oral dose of 2.5 mg daily to 12 patients for 16 weeks (B) and to 64 patients for 12 weeks (E). Treatment was administered until the day of surgery.
	According to protocol, tumors included in the E data set underwent tissue sampling (Tru-cut biopsies) before commencing treatment and after two weeks on therapy, followed by sampling at surgery (three months). As for the tumors included in the B data set, these tumors all had an incisional biopsy prior to commencing treatment and secondary sampling at surgery (three months). 
Tumor size was estimated by calculating the product of the largest diameter and its perpendicular. The patients were classified as responders or non-responders depending on more or less than 50% reduction in tumor size, respectively. In the two B data sets  ADDIN EN.CITE [, ] clinical response was assessed by clinical tumor measurement using a caliper and seventeen patients were classified as responders, whereas four were classified as non-responders. In the E data set  ADDIN EN.CITE [] tumor assessment was performed by ultrasound measurements of the tumors; here, 35 patients were classified as responders, 15 were non-responders whereas 14 of the patients were set to be unclassified because of inconsistencies in response assessment  ADDIN EN.CITE []. Breast tumor tissue available for gene expression analysis was collected by core-cut (E) or incisional biopsy (B) prior to treatment, after 10-14 days of treatment (64 patients from E) and during final surgery (all patients). The E and B data sets are presented separately because of the different measurement techniques in response classification.

2.3. Histochemical methods
ER and HER-2/neu were analysed using standard immunohistochemical methods as already published  ADDIN EN.CITE []. ER was reported as percentage of positively stained cells, and the tumors were considered positive if ≥10% of the cells stained for ER (B), or by an Allred score (E) of ≥ 5  ADDIN EN.CITE []. 
	For pAkt labelling, the sections were pre-treated with 1x Target Retrieval Solution pH 9 (Dako) for 12 minutes using jet steam microwaves. Then the sections were blocked using Odyssey blocking buffer (Li-COR Biosciences) diluted 1:1 in Tris buffered saline with 0.1% Tween (TBST) for 40 minutes at room temperature. The sections were incubated with rabbit anti-pAktser473 antibody (Cell Signaling Technology) diluted 1:50 in Odyssey blocking buffer/TBST 1:1 overnight at 4ºC. Subsequently, the sections were incubated with donkey anti-rabbit antibody conjugated with IR-680 dye (Li-COR Biosciences) diluted 1:1000 in Odyssey blocking buffer/TBST 1:1 for 40 minutes at room temperature. Negative control sections were prepared by incubating only with the secondary antibody. Near infrared immunofluorescent imaging was performed as described previously  ADDIN EN.CITE []. The pAktSer473 staining intensity was measured using Image Studio 3.1.

2.4. Quantitative Real-time PCR
RNA extraction and revers transcription of the samples have been described previously  ADDIN EN.CITE [, ]. Quantitative real-time PCR was performed using gene-specific primers and probes designed from the Universal Probe Library (UPL, Roche, Basel, Switzerland, Supplementary Table 1). In three parallels, each target gene was quantified in duplex with TATA binding protein (TBP) using the UPL TBP Human gene assay using the LightCycler 480 System (Roche). Amplification reaction mixture consisted of 1.5 µL diluted cDNA, 7.5 µL LC480 Probe Master mix (Roche), 0.4 µmol/L of each primer, 0.1 µmol/L of UPL probe, 0.1 µmol/L of TBP reference primers and 0.1 µmol/L TBP reference probe in a total volume of 15 µL. Thermocycling setup was as following: pre-incubation at 95 ºC for 10 minutes, 45 cycles with denaturation at 95 ºC for 10 seconds, primer annealing at 60 ºC for 30 seconds and DNA sequence extension at 72 ºC for 1 second followed by fluorescence measurement.

2.5. Akt1 and PI3CA mutation analyses
Genomic DNA was isolated from tumor tissue from the 21 patients from the B data set. We analyzed Akt1 for detection of the Akt1 E17K mutation in exon 4 and PI3CA for detection of PI3CA E542K in exon 9 in addition to H1047R and M1043I in exon 20. Mutation analyses were performed by PCR amplification of the relevant exons and subsequent Sanger sequencing. Akt1 exon 4 was amplified in a nested PCR using the Dynazyme polymerase system (Finnzymes) according to the manufacturer’s instructions. First round of amplification was performed with forward primer cacatctgtcctggcacacc and reverse primer CTTAGGACTCAGCCTGGAGAC, while second round was performed with forward primer gtagagtgtgcgtggctctc and reverse primer CTTGTTG-CTTGCCAGCCCAG. The thermocycling conditions for both rounds were an initial denaturation step of 5 minutes at 94ºC followed by 35 cycles of 1 minute at 94ºC, 30 seconds at 63.9ºC and 1 minute at 72ºC, and a final elongation step of 7 minutes at 72ºC. PI3KCA exons 9 and 20 were amplified using Kod XL polymerase system (Novagen) according to the manufacturer’s instructions, with forward primer GGGAAAAATATGACAAAGAAAGC and reverse primer CTGAGATCAGCCAAATT-CAGTT for exon 9 and forward primer gctccaaactgaccaaactgttc and reverse primer TGGAATCCAGAGTGAGCTTTC for exon 20. For both PI3KCA exons, the thermocycling conditions were an initial denaturation step of 5 minutes at 94ºC followed by 35 cycles of 30 seconds at 94ºC, 3 seconds at 60.1ºC and 5 seconds at 72ºC, and a final elongation step of 7 minutes at 72ºC. DNA sequencing was performed using the BigDye v1.1 terminator sequencing system (Applied Biosystems).

2.6. Statistical analysis
The mRNA expression levels of target genes were normalized by expression of TBP. Geometric means of replicas were presented with 95% confidence interval (CI) of the mean. Differences in mRNA levels between HER-2/neu amplified and non-amplified subjects in addition to differences between responders and non-responders were analyzed using the non-parametric Mann-Whitney U rank test of independent samples. Differences in mRNA expression levels between time points of treatment were analyzed using the non-parametric Friedman`s and Wilcoxon tests. Statistical analyses of mutations in addition to response rates between data sets were analyzed using Fisher exact test. All analyses were performed using the software IBM SPSS Statistics 19. 


3. Results:
3.1. Pretreatment HER-receptors and ligand expression levels as potential predictors of response to aromatase inhibitor treatment
Using gene-specific primers and probes, mRNA levels of EGFR/HER-1, HER-2/neu, HER-3, HER-4 and NRG1 were analyzed in ER positive tumor samples before and during AI treatment using real-time PCR. Whereas all four HER-receptors were detectable in >95% of the tumor samples, NRG1 was detectable in 89.7% of the samples only (Supplementary Table 2). Consequently, the number of observations used for the different calculations may vary.
We found HER-2/neu amplified tumors to exhibit significantly higher HER-2/neu mRNA levels (Geometric mean (GM): 2.52, Confidence interval (CI): 1.14-5.55) compared to HER-2/neu non-amplified tumors (GM: 0.72, CI: 0.59-0.88; P = 0.001, data not shown). Consequently, HER-2/neu amplified and non-amplified tumors are presented separately. 
No correlation between pretreatment HER-2/neu, EGFR/HER-1, HER-3, HER-4 or NRG1 expression levels and response to treatment was recorded in any of the data sets (B and E) (results not shown).

3.2. Changes in growth factor receptor expression during treatment with aromatase inhibitor 
Pre-treatment tumor samples and samples collected at surgery from the data sets (B and E) were available for gene expression analysis. Additionally, tumor samples collected at two weeks of treatment were available from the E data set, and samples collected at all three time points (before therapy, after two weeks and three months on treatment) were available from 48 patients. Analyzing HER-receptors and NRG1 expression levels across the E data set, we found significant different expression levels for EGFR/HER-1 and NRG1 between the three time points (before therapy, after two weeks and after three months on treatment; P ≤ 0.001 for both; Table 2). No significant difference in expression level of HER-2/neu, HER-3 or HER-4 was recorded. Similar, no significant differences in expression levels for any of the parameters were recorded in HER-2/neu amplified tumors (data not shown).

Table 2. Significant differences in tumor HER-receptors and NRG1 levels during AI-treatment.
Gene	χ2	n	P-valuea
EGFR/HER-1	28.95	44	≤ 0.001
HER-2/neu	4.62	42	0.099
HER-3	2.21	47	0.331
HER-4	0.30	47	0.862
NRG1	27.62	37	≤ 0.001



a P-value on the Friedman`s test comparing mean ranks of tumor mRNA levels between before and at two weeks and three months on treatment.
χ2; Chi-Square

We did not observe any difference in clinical response rate between the data sets (B and E) (P = 0.395, Fisher exact test, data not shown). Table 3 summarizes the expression levels of EGFR/HER-1 and NRG1 before and at three months on treatment in the data sets. The E data set showed highly significant changes for both EGFR/HER-1 and NRG1 (P ≤ 0.001 for both) during AI-treatment, and the B data set approached but fell short of significance due to low number of patients (n=19). By combining these data sets and including all HER-2/neu non-amplified tumors (n=68, E and B), we observed an overall significant increase in EGFR/HER-1 (fold change (FC): 2.03, 95% CI: (1.53-2.68), 51 up and 13 down, P ≤ 0.001) and NRG1 (FC: 2.47 (1.75-3.48), 49 up of 14 down, P ≤ 0.001, data not shown) after three months of treatment with AIs as compared to pretreatment levels. 





Table 3. EGFR/HER-1 and NRG1 expression levels during AI-treatment.
Data set	Gene	Before treatment	3 months	n	Fold change	P-valueb
E	EGFR/HER-1	0.51 (0.39-0.67)a	1.19 (1.00-1.43)	48	2.25 (1.66-3.04)	≤0.001
	NRG1	0.27 (0.19-0.38)	0.71 (0.54-0.93)	41	2.66 (1.90-3.73)	≤0.001
B	EGFR/HER-1	0.17 (0.10-0.30)	0.27 (0.18-0.38)	19	1.58 (0.83-3.02)	0.117
	NRG1	0.61 (0.26-1.44)	1.28 (0.77-2.11)	19	2.10 (0.89-4.99)	0.227
a mRNA levels presented as geometric mean (95% confidence interval)
b Differences in mRNA expression were analyzed using the non-parametric Wilcoxon test

 

Pair-wise comparison revealed a significant increase in EGFR/HER-1 levels during the first two weeks of estrogen deprivation (P = 0.049), although there was a substantial inter-individual variation (Fig. 1). No significant change in NRG1 expression level was recorded during that time interval. Finally, comparing expression levels between samples obtained after two weeks and three months on treatment, a significantly increase in expression levels for both parameters was recorded (P = 0.001 for both; Fig. 1)


(Figure 1 is presented in a separate file, 2 column)

Fig. 1. EGFR/HER-1 and NRG1 during treatment with aromatase inhibitors. 
Relative EGFR/HER-1 and NRG1 tumors levels before treatment, at two weeks and at three months on aromatase inhibitors from patients with ER positive / HER-2/neu non-amplified disease in the E data set. Each bar represents one patient and the height of each segment in the stacked bar reflects the expression level at each time point. The mRNA levels were quantified using gene specific primers and probes using real time PCR. 



3.3. Correlations between alterations in growth factor receptor expression and response to therapy 

Next, we wanted to determine whether changes in HER-receptors and NRG1 could be related to clinical response. No significant difference in expression levels of any parameter between responders or non-responders for any of the HER-receptors or NRG1 was recorded after either two weeks or three months on therapy (data not shown). 

3.4. PIK3CA mutations and pAKT activation
Genomic DNA was available from the 21 patients in the B cohort. Here, mutational analyses revealed one tumor to be Akt1 E17K mutated, while five, seven and one tumor harbored the PI3CA mutations E542K, H1047R and M1043I, respectively (Supplementary Table 3). No associations between changes in expression levels of any of the HER-receptors or NRG1 and PI3CA mutations were recorded in the tumors bearing PI3CA mutations. Further, we wanted to elucidate potential associations between the PI3CA mutations and response to treatment in the selected patient group. While the PI3CA E542K mutation in exon 9 was observed among two responders and three non-responders, interestingly the seven PI3CA H1047R mutations and the single M1043I mutation in exon 20 all were observed among responders (Fig. 2). The H1047R mutation was significantly associated with treatment response (P = 0.035). Additionally, the activity of the downstream signaling mTOR pathway was analyzed by studying the level of phosphorylated Akt before and after estrogen deprivation in tumors from a subset of 10 patients. No significant change in pAKT levels during estrogen deprivation was observed. In addition, no associations between changes in HER-receptors or NRG1 and pAKT levels were recorded (Supplementary Table 3).


(Figure 2 is presented in a separate file, 1.5 column)

Fig. 2. PI3CA mutations and treatment response.
Illustration of PI3CA exon 9 (E542K) and exon 20 (M1043I and H1047R) mutated and wild type (WT) genes in breast cancer tumors from all patients analyzed (B, n=21), responders (n=16) and non-responders (n=5). Mutational analyses were performed by PCR amplification of the relevant exons and subsequent Sanger sequencing.

4. Discussion: 
Experimental evidence has shown dysregulation of growth factor signaling networks to play a role in endocrine resistance to AIs  ADDIN EN.CITE [, ]. In the present study, we explored the potential role of altered expression of all four HER-receptors and the HER-3/4 neuregulin-1 (NRG1) ligand as predictors of response to treatment with AIs, and observed a significant increase in EGFR/HER-1 and NRG1 expression during three months of treatment. However, no difference in expression levels between tumors responding and those not responding to therapy was recorded. To our knowledge, this is the first study focusing on the mRNA expression of all HER-receptors and NRG1 in matched samples from breast cancer patients before and during treatment with AIs.
Treatment with AIs for 3-4 months suppresses total body estrogen synthesis by >98% in most patients  ADDIN EN.CITE []. Our findings of an increased EGFR/HER-1 and NRG1 expression in the majority of ER positive breast tumors during aromatase inhibition are consistent with in vitro studies, revealing estrogens to suppress EGFR/HER-1 transcription through a negative regulatory element within the first intron of EGFR/HER-1  ADDIN EN.CITE []. In line with this we recently demonstrated EGFR/HER-1 to negatively correlate with estrogens in untreated breast cancer []. Thus, increased levels of EGFR/HER-1 may reflect a primary molecular response to estrogen deprivation in the cancer cells. 
During blockage of the ER signaling pathway in ER positive breast cancer other survival pathways must be activated for the cancer cells to grow. We observed the increase in EGFR/HER-1 and NRG1 expression levels to be independent of clinical response at three months of treatment with AIs. The majority of patients included in this study still responded to treatment after three months, however, acquired resistance to endocrine treatment may develop as a consequence of a serial of complex adaptive changes occurring in breast cancer cells during the selective pressure of long-term endocrine treatment []. Notably, in vitro studies have linked both EGFR/HER-1 and NRG1 expression levels to endocrine resistance  ADDIN EN.CITE []. Thus, the possibility exists that induction of EGFR/HER-1 during antihormone therapy may affect proliferation over time, leaving cells more sensitive to mitogenic effects of growth factors  ADDIN EN.CITE [].
In the present study we observed a small increase of EGFR/HER-1 already at two weeks on treatment with AIs, but the increase in EGFR/HER-1 and NRG1 was most prominent from two weeks to three months on treatment. Gene expression profiling of tumor biopsies from a proportion of patients included in this study has previously revealed that substantially more genes were changed at three months than at two weeks on AI treatment []. Thus, the changes in EGFR/HER-1 and in particular NRG1 could be related to tumor heterogeneity and clonal selection potentially related to primary effects of deregulated ER- signaling in the tumors  ADDIN EN.CITE [, , ]. 
	Clinical observations have revealed endocrine therapy to work poorly in tumors with activation of the HER-2/neu pathway  ADDIN EN.CITE [], and cross-talk between ER and HER-2/neu has been suggested to be a major contributor to endocrine resistance  ADDIN EN.CITE [, ]. While an inverse relationship normally exists between HER-2/neu amplification and ER expression  ADDIN EN.CITE [], we and others have shown HER-2/neu and ER mRNA (ERS1) expression levels to be positively associated in HER-2/neu non-amplified tumors  ADDIN EN.CITE [, ]. On the other hand, a negative association was demonstrated between EGFR/HER-1 and ERS1 in ER positive HER-2/neu non-amplified tumors []. The increase in EGFR/HER-1 and NRG1 during estrogen deprivation reported in the present clinical study supports the role of an intimate cross-talk between ER and growth factor receptor signaling pathways during endocrine treatment  ADDIN EN.CITE [, ] .	Using different in vitro models mimicking AI resistance, increased expression of HER-receptors, and in particular EGFR/HER-1, accompanied by diminished ER-regulated signaling has been demonstrated  ADDIN EN.CITE [, , ]. However, the knowledge of EGFR/HER-1 and NRG1 expression and activity in breast tumors during AI therapy and development of resistance is limited. Interestingly, a recent clinical investigation of the biological effects during treatment with the anti-estrogen fulvestrant showed a modest increase in EGFR/HER-1 activity at relapse in 65% of the patients  ADDIN EN.CITE []. Detailed studies of the HER-receptors in breast tumor tissue at AI relapse should be performed to comprehend the role of HER-receptors in AI resistance.  
	The mechanisms underlying breast tumor progression involve many complex intracellular networks. Compensatory relationships exist between ER and growth factor signaling, where blockage of one of them may lead to activation of the other  ADDIN EN.CITE [, , , ], and it has recently been shown that EGF-driven signaling can overrule tamoxifen-mediated inhibition of MCF-7 breast cancer cell proliferation []. Thus, combinatorial treatment blocking both ER and growth factor signaling pathways has been suggested to be the most effective inhibition of proliferation in ER positive breast cancer cells  ADDIN EN.CITE [, , , , ]. In line with this, treatment with the MAPK/ERK kinase inhibitor, selumetinib reversed the AI resistance in mice exhibiting anastrozole resistant tumors  ADDIN EN.CITE []. Adding the dual EGFR/HER-1 / HER-2/neu inhibitor lapatinib to the AI inhibitor letrozole improved the progression free survival (PFS) in patients with ER positive/HER-2/neu amplified tumors, whereas no effects were observed in the ER positive/HER-2/neu non-amplified subgroup  ADDIN EN.CITE []. However, an interesting trend toward prolonged PFS was shown for lapatinib and letrozole in patients with ER positive/HER-2/neu non-amplified disease who experienced relapse after tamoxifen treatment  ADDIN EN.CITE []. Recently, it was also reported that addition of lapatinib to letrozole improved the PFS in patients with advanced ER-positive HER-2/neu non-amplified breast cancer that had lower expression of ER by H-score  ADDIN EN.CITE []. On the other hand, studies so far have failed to support the hypothesis that addition of the EGFR/HER-1 inhibitor gefitinib to the AI-inhibitor anastrozole could improve the clinical outcome of patients with ER-positive breast cancer  ADDIN EN.CITE [, ].
Cross-talk between ER and growth factor receptors also involves non-genomic activation of ER []. The seven-transmembrane G-protein-coupled estrogen receptor-1 (GPER-1) activates non-genomic estrogen signaling in various tissues [], and triggers EGFR/HER-1, MAPK/ERK and PI3K/AKT signaling pathways regulating cell migration, survival and proliferation  ADDIN EN.CITE [, ]. In a clinical study, co-expression of ER and GPER-1 was shown in approximately 40% of the breast cancers, but the knowledge of GPER-1 in ER positive breast tumors is limited. Interestingly, it has been reported that tamoxifen acts as an agonist of GPER-1 [], suggesting a potential role of GPER-1 in tamoxifen resistance. Moreover, long-term endocrine treatment with tamoxifen facilitates the translocation of GPER-1 to the cell surface interferring with EGFR/HER-1 signaling pathway  ADDIN EN.CITE []. Whether GPER-1 is involved in the AI induced stimulation of EGFR/HER-1 and NRG1 reported here remains to be investigated. 
Activation of the PI3K-AKT-mTOR signaling pathway, acting downstream to HER-2/neu, has been suggested to be one mechanism of resistance to endocrine therapy  ADDIN EN.CITE [, ]. However, while the mTOR inhibitor everolimus has been shown to improve efficacy of treatment and progression-free survival in ER-positive postmenopausal patients when combined with an AI compared to AI alone  ADDIN EN.CITE [, ], the effect was moderate. We did not observe changes in pAKT levels during estrogen deprivation in the present study. However, analyzing for PI3CA gain of function mutations [], we found the PI3CA H1047R, but not the E542K and M1043I mutations to be associated with response to treatment. While PIK3CA mutations have been associated with better response to endocrine therapy in ER-positive HER-2/neu negative breast cancer  ADDIN EN.CITE [, ], due to the small number of tumors and genomic DNA samples available for protein and mutational analysis in our study these findings must be interpreted with caution []. 
In a small subset of tumors examined here, EGFR/HER-1 and NRG1 decreased during AI therapy. In vitro and in vivo xenograft studies analyzing adaptive signaling events in the development of resistance have revealed that the cellular changes are complex and may vary in-between model systems  ADDIN EN.CITE [, , , ]. Analyses of global gene expression have also shown that the effects of estrogen deprivation may vary in-between patients even within the subset of ER positive / HER-2/neu non-amplified tumors [].
This study has some limitations. Tumor samples have been collected from three different study protocols at two sites, and there are some differences in patient treatment and tumor measurements. Further studies on samples from patients with recurrence after AI treatment are needed to assess the roles of EGFR/HER-1 and NRG1 in AI resistance. The biological effects related to changes in EGFR/HER-1 and NRG1 expression that we report in the present study should be examined in more detail. In vitro it has been shown that a small increase in EGFR/HER-1 mRNA expression leads to marked changes in EGFR/HER-1 protein levels []. Small changes in gene expression may have important phenotypic effects depending on the type of gene. In another clinical study, ER-positive breast cancer patients were treated with AIs for 2 weeks prior to surgery and the gene expression changes were integrated into a Global Index of Dependence on Estrogen (GIDE) defined as the number of genes changing by at least twofold between each pair of biopsies. This index correlated positively with change in the proliferation marker Ki67, and turned out to be a useful approach to characterize the overall biological reactivity of a tumor to estrogen deprivation  ADDIN EN.CITE []. 
In summary, we observed significant increase in EGFR/HER-1 and NRG1 during estrogen deprivation in paired pre- and on-treatment ER positive / HER-2/neu non-amplified tumors. The rise in EGFR/HER-1 and NRG1 may be interpreted as an early molecular response to AI treatment, and future studies are required to determine the implications for development of acquired resistance during long-term endocrine treatment, as well as the potential advantage of combinational therapy with AIs and drugs targeting NRG1 or its signaling pathways.

Acknowledgements:

The study was supported by the Norwegian Cancer Society (https://kreftforeningen.no (​https:​/​​/​kreftforeningen.no​/​​)), The Western Norway Regional Health Authority (http://www.helse-bergen.no/forskning/samarbeidsorganet (​http:​/​​/​www.helse-bergen.no​/​forskning​/​samarbeidsorganet​)), Odd Fellow Medisinsk Vitenskapelig Forskningsfond (oddfellow.no) and Martin Flatners legat.


References
[1] P.E. Lonning, The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum, Ann Oncol, 22 (2011) 503-514.[2] W.R. Miller, Aromatase inhibitors: prediction of response and nature of resistance, Expert Opin Pharmacother, 11 (2010) 1873-1887.[3] P.E. Lonning, H.P. Eikesdal, Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved, Endocr Relat Cancer, 20 (2013) R183-201.[4] M. Dowsett, C. Allred, J. Knox, E. Quinn, J. Salter, C. Wale, J. Cuzick, J. Houghton, N. Williams, E. Mallon, H. Bishop, I. Ellis, D. Larsimont, H. Sasano, P. Carder, A.L. Cussac, F. Knox, V. Speirs, J. Forbes, A. Buzdar, Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial, J Clin Oncol, 26 (2008) 1059-1065.[5] M. Dowsett, J. Houghton, C. Iden, J. Salter, J. Farndon, R. A'Hern, R. Sainsbury, M. Baum, Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status, Ann Oncol, 17 (2006) 818-826.[6] S.J. Houston, T.A. Plunkett, D.M. Barnes, P. Smith, R.D. Rubens, D.W. Miles, Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer, Brit J Cancer, 79 (1999) 1220-1226.[7] B.B. Rasmussen, M.M. Regan, A.E. Lykkesfeldt, P. Dell'Orto, B. Del Curto, K.L. Henriksen, M.G. Mastropasqua, K.N. Price, E. Mery, M. Lacroix-Triki, S. Braye, H.J. Altermatt, R.D. Gelber, M. Castiglione-Gertsch, A. Goldhirsch, B.A. Gusterson, B. Thurlimann, A.S. Coates, G. Viale, B.I.G. Collaborative, G. International Breast Cancer Study, Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial, Lancet Oncol, 9 (2008) 23-28.[8] S. Hole, A.M. Pedersen, S.K. Hansen, J. Lundqvist, C.W. Yde, A.E. Lykkesfeldt, New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane, Int J Oncol, 46 (2015) 1481-1490.[9] S.L. Tilghman, I. Townley, Q. Zhong, P.P. Carriere, J. Zou, S.D. Llopis, L.C. Preyan, C.C. Williams, E. Skripnikova, M.R. Bratton, Q. Zhang, G. Wang, Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness, Mol Cell Proteomics, 12 (2013) 2440-2455.[10] L.A. Martin, I. Farmer, S.R. Johnston, S. Ali, C. Marshall, M. Dowsett, Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation, J Biol Chem, 278 (2003) 30458-30468.[11] H. Aguilar, X. Sole, N. Bonifaci, J. Serra-Musach, A. Islam, N. Lopez-Bigas, M. Mendez-Pertuz, R.L. Beijersbergen, C. Lazaro, A. Urruticoechea, M.A. Pujana, Biological reprogramming in acquired resistance to endocrine therapy of breast cancer, Oncogene, 29 (2010) 6071-6083.[12] D. Jelovac, G. Sabnis, B.J. Long, L. Macedo, O.G. Goloubeva, A.M. Brodie, Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole, Cancer Res, 65 (2005) 5380-5389.[13] G. Sabnis, O. Goloubeva, R. Gilani, L. Macedo, A. Brodie, Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment, Molecular cancer therapeutics, 9 (2010) 46-56.[14] A. Brodie, D. Jelovac, L. Macedo, G. Sabnis, S. Tilghman, O. Goloubeva, Therapeutic observations in MCF-7 aromatase xenografts, Clin Cancer Res, 11 (2005) 884s-888s.[15] L.A. Martin, I. Farmer, S.R. Johnston, S. Ali, M. Dowsett, Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation, Endocr Relat Cancer, 12 Suppl 1 (2005) S75-84.[16] T.W. Miller, B.T. Hennessy, A.M. Gonzalez-Angulo, E.M. Fox, G.B. Mills, H. Chen, C. Higham, C. Garcia-Echeverria, Y. Shyr, C.L. Arteaga, Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer, J Clin Invest, 120 (2010) 2406-2413.[17] G.J. Sabnis, D. Jelovac, B. Long, A. Brodie, The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation, Cancer Res, 65 (2005) 3903-3910.[18] G. Sabnis, A. Brodie, Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance, Mol Cell Endocrinol, 340 (2011) 142-147.[19] W. Yue, P. Fan, J. Wang, Y. Li, R.J. Santen, Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells, J Steroid Biochem Mol Biol, 106 (2007) 102-110.[20] S. Masri, S. Phung, X. Wang, S. Chen, Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines, J Steroid Biochem Mol Biol, 118 (2010) 277-282.[21] M.A. Olayioye, R.M. Neve, H.A. Lane, N.E. Hynes, The ErbB signaling network: receptor heterodimerization in development and cancer, EMBO J, 19 (2000) 3159-3167.[22] Y. Yarden, M.X. Sliwkowski, Untangling the ErbB signalling network, Nat Rev Mol Cell Biol, 2 (2001) 127-137.[23] D. Graus-Porta, R.R. Beerli, J.M. Daly, N.E. Hynes, ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling, EMBO J, 16 (1997) 1647-1655.[24] T. Holbro, R.R. Beerli, F. Maurer, M. Koziczak, C.F. Barbas, 3rd, N.E. Hynes, The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation, Proc Natl Acad Sci U S A, 100 (2003) 8933-8938.[25] J. Baselga, V. Semiglazov, P. van Dam, A. Manikhas, M. Bellet, J. Mayordomo, M. Campone, E. Kubista, R. Greil, G. Bianchi, J. Steinseifer, B. Molloy, E. Tokaji, H. Gardner, P. Phillips, M. Stumm, H.A. Lane, J.M. Dixon, W. Jonat, H.S. Rugo, Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer, J Clin Oncol, 27 (2009) 2630-2637.[26] B. Kaufman, J.R. Mackey, M.R. Clemens, P.P. Bapsy, A. Vaid, A. Wardley, S. Tjulandin, M. Jahn, M. Lehle, A. Feyereislova, C. Revil, A. Jones, Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study, J Clin Oncol, 27 (2009) 5529-5537.[27] J. Geisler, S. Detre, H. Berntsen, L. Ottestad, B. Lindtjorn, M. Dowsett, P. Einstein Lonning, Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer, Clin Cancer Res, 7 (2001) 1230-1236.[28] J. Geisler, H. Helle, D. Ekse, N.K. Duong, D.B. Evans, Y. Nordbo, T. Aas, P.E. Lonning, Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels, Clin Cancer Res, 14 (2008) 6330-6335.[29] W.R. Miller, A. Larionov, L. Renshaw, T.J. Anderson, J.R. Walker, A. Krause, T. Sing, D.B. Evans, J.M. Dixon, Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole, J Clin Oncol, 27 (2009) 1382-1387.[30] J.M. Harvey, G.M. Clark, C.K. Osborne, D.C. Allred, Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer, J Clin Oncol, 17 (1999) 1474-1481.[31] W.R. Miller, A.A. Larionov, L. Renshaw, T.J. Anderson, S. White, J. Murray, E. Murray, G. Hampton, J.R. Walker, S. Ho, A. Krause, D.B. Evans, J.M. Dixon, Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole, Pharmacogenet Genomics, 17 (2007) 813-826.[32] S.A. Moestue, C.G. Dam, S.S. Gorad, A. Kristian, A. Bofin, G.M. Maelandsmo, O. Engebraten, I.S. Gribbestad, G. Bjorkoy, Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer, Breast Cancer Res, 15 (2013) R16.[33] M.H. Flageng, S. Knappskog, B.P. Haynes, P.E. Lonning, G. Mellgren, Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue, PloS one, 8 (2013) e74618.[34] J. Geisler, B. Haynes, G. Anker, M. Dowsett, P.E. Lonning, Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study, J Clin Oncol, 20 (2002) 751-757.[35] J. Geisler, N. King, M. Dowsett, L. Ottestad, S. Lundgren, P. Walton, P.O. Kormeset, P.E. Lonning, Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer, Br J Cancer, 74 (1996) 1286-1291.[36] J. Geisler, N. King, G. Anker, G. Ornati, E. Di Salle, P.E. Lonning, M. Dowsett, In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients, Clin Cancer Res, 4 (1998) 2089-2093.[37] R.I. Yarden, M.A. Wilson, S.A. Chrysogelos, Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth, J Cell Biochem Suppl, Suppl 36 (2001) 232-246.[38] M.A. Wilson, S.A. Chrysogelos, Identification and characterization of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone-dependent breast cancer cells, Journal of cellular biochemistry, 85 (2002) 601-614.[39] J.M. Gee, M.E. Harper, I.R. Hutcheson, T.A. Madden, D. Barrow, J.M. Knowlden, R.A. McClelland, N. Jordan, A.E. Wakeling, R.I. Nicholson, The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro, Endocrinology, 144 (2003) 5105-5117.[40] T.W. Miller, J.M. Balko, C.L. Arteaga, Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer, J Clin Oncol, 29 (2011) 4452-4461.[41] T. van Agthoven, A.M. Sieuwerts, D. Meijer, M.E. Meijer-van Gelder, T.L. van Agthoven, R. Sarwari, S. Sleijfer, J.A. Foekens, L.C. Dorssers, Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response, Endocr Relat Cancer, 17 (2010) 215-230.[42] W.R. Miller, A. Larionov, T.J. Anderson, D.B. Evans, J.M. Dixon, Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole, Pharmacogenomics J, 12 (2012) 10-21.[43] L.R. Yates, M. Gerstung, S. Knappskog, C. Desmedt, G. Gundem, P. Van Loo, T. Aas, L.B. Alexandrov, D. Larsimont, H. Davies, Y. Li, Y.S. Ju, M. Ramakrishna, H.K. Haugland, P.K. Lilleng, S. Nik-Zainal, S. McLaren, A. Butler, S. Martin, D. Glodzik, A. Menzies, K. Raine, J. Hinton, D. Jones, L.J. Mudie, B. Jiang, D. Vincent, A. Greene-Colozzi, P.Y. Adnet, A. Fatima, M. Maetens, M. Ignatiadis, M.R. Stratton, C. Sotiriou, A.L. Richardson, P.E. Lonning, D.C. Wedge, P.J. Campbell, Subclonal diversification of primary breast cancer revealed by multiregion sequencing, Nat Med, 21 (2015) 751-759.[44] A. Mackay, A. Urruticoechea, J.M. Dixon, T. Dexter, K. Fenwick, A. Ashworth, S. Drury, A. Larionov, O. Young, S. White, W.R. Miller, D.B. Evans, M. Dowsett, Molecular response to aromatase inhibitor treatment in primary breast cancer, Breast Cancer Res, 9 (2007) R37.[45] M. De Laurentiis, G. Arpino, E. Massarelli, A. Ruggiero, C. Carlomagno, F. Ciardiello, G. Tortora, D. D'Agostino, F. Caputo, G. Cancello, E. Montagna, L. Malorni, L. Zinno, R. Lauria, A.R. Bianco, S. De Placido, A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer, Clin Cancer Res, 11 (2005) 4741-4748.[46] G. Arpino, L. Wiechmann, C.K. Osborne, R. Schiff, Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance, Endocr Rev, 29 (2008) 217-233.[47] M.J. Ellis, Y. Tao, O. Young, S. White, A.D. Proia, J. Murray, L. Renshaw, D. Faratian, J. Thomas, M. Dowsett, A. Krause, D.B. Evans, W.R. Miller, J.M. Dixon, Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole, J Clin Oncol, 24 (2006) 3019-3025.[48] G. Konecny, G. Pauletti, M. Pegram, M. Untch, S. Dandekar, Z. Aguilar, C. Wilson, H.M. Rong, I. Bauerfeind, M. Felber, H.J. Wang, M. Beryt, R. Seshadri, H. Hepp, D.J. Slamon, Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer, J Natl Cancer Inst, 95 (2003) 142-153.[49] I. Pinhel, M. Hills, S. Drury, J. Salter, G. Sumo, R. A'Hern, J.M. Bliss, I. Sestak, J. Cuzick, P. Barrett-Lee, A. Harris, M. Dowsett, N.A.B.C.T.M. Group, ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer, Breast Cancer Res, 14 (2012) R46.[50] A. Agrawal, J.F. Robertson, K.L. Cheung, E. Gutteridge, I.O. Ellis, R.I. Nicholson, J.M. Gee, Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies, Int J Cancer, 138 (2016) 146-159.[51] K. Sonne-Hansen, I.C. Norrie, K.B. Emdal, R.V. Benjaminsen, T. Frogne, I.J. Christiansen, T. Kirkegaard, A.E. Lykkesfeldt, Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance, Breast Cancer Res Treat, 121 (2010) 601-613.[52] M. Moerkens, Y. Zhang, L. Wester, B. van de Water, J.H. Meerman, Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor alpha signalling and results in tamoxifen insensitive proliferation, BMC Cancer, 14 (2014) 283.[53] G. Sabnis, O. Goloubeva, D. Jelovac, A. Schayowitz, A. Brodie, Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens, Clin Cancer Res, 13 (2007) 2751-2757.[54] G. Sabnis, A. Schayowitz, O. Goloubeva, L. Macedo, A. Brodie, Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen, Cancer Res, 69 (2009) 1416-1428.[55] G.J. Sabnis, A. Kazi, O. Golubeva, P. Shah, A. Brodie, Effect of selumetinib on the growth of anastrozole-resistant tumors, Breast Cancer Res Treat, 138 (2013) 699-708.[56] S. Johnston, J. Pippen, Jr., X. Pivot, M. Lichinitser, S. Sadeghi, V. Dieras, H.L. Gomez, G. Romieu, A. Manikhas, M.J. Kennedy, M.F. Press, J. Maltzman, A. Florance, L. O'Rourke, C. Oliva, S. Stein, M. Pegram, Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer, J Clin Oncol, 27 (2009) 5538-5546.[57] R.S. Finn, M.F. Press, J. Dering, L. O'Rourke, A. Florance, C. Ellis, A.M. Martin, S. Johnston, Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer, Clin Cancer Res, 20 (2014) 736-743.[58] K. Tryfonidis, G. Basaran, J. Bogaerts, M. Debled, L. Dirix, J.C. Thery, V.C. Tjan-Heijnen, D. Van den Weyngaert, T. Cufer, M. Piccart, D. Cameron, E.O.-B.C. Group, A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378), Eur J Cancer, 53 (2016) 144-154.[59] R.W. Carlson, A. O'Neill, T. Vidaurre, H.L. Gomez, S.S. Badve, G.W. Sledge, A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer, Breast Cancer Res Treat, 133 (2012) 1049-1056.[60] B. Manavathi, O. Dey, V.N. Gajulapalli, R.S. Bhatia, S. Bugide, R. Kumar, Derailed estrogen signaling and breast cancer: an authentic couple, Endocr Rev, 34 (2013) 1-32.[61] E.J. Filardo, P. Thomas, Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology, Endocrinology, 153 (2012) 2953-2962.[62] E.J. Filardo, J.A. Quinn, A.R. Frackelton, Jr., K.I. Bland, Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis, Mol Endocrinol, 16 (2002) 70-84.[63] R. Lappano, P. De Marco, E.M. De Francesco, A. Chimento, V. Pezzi, M. Maggiolini, Cross-talk between GPER and growth factor signaling, J Steroid Biochem Mol Biol, 137 (2013) 50-56.[64] E.R. Prossnitz, M. Barton, The G-protein-coupled estrogen receptor GPER in health and disease, Nat Rev Endocrinol, 7 (2011) 715-726.[65] Z. Mo, M. Liu, F. Yang, H. Luo, Z. Li, G. Tu, G. Yang, GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer, Breast Cancer Res, 15 (2013) R114.[66] S.R. Johnston, Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer, Clin Cancer Res, 12 (2006) 1061s-1068s.[67] J. Baselga, J. Cortes, S.B. Kim, S.A. Im, R. Hegg, Y.H. Im, L. Roman, J.L. Pedrini, T. Pienkowski, A. Knott, E. Clark, M.C. Benyunes, G. Ross, S.M. Swain, C.S. Group, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, N Engl J Med, 366 (2012) 109-119.[68] S. Di Cosimo, J. Baselga, Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation?, Clin Cancer Res, 15 (2009) 5017-5019.[69] S. Loi, B. Haibe-Kains, S. Majjaj, F. Lallemand, V. Durbecq, D. Larsimont, A.M. Gonzalez-Angulo, L. Pusztai, W.F. Symmans, A. Bardelli, P. Ellis, A.N. Tutt, C.E. Gillett, B.T. Hennessy, G.B. Mills, W.A. Phillips, M.J. Piccart, T.P. Speed, G.A. McArthur, C. Sotiriou, PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer, Proc Natl Acad Sci U S A, 107 (2010) 10208-10213.[70] D.E. Ramirez-Ardila, J.C. Helmijr, M.P. Look, I. Lurkin, K. Ruigrok-Ritstier, S. van Laere, L. Dirix, F.C. Sweep, P.N. Span, S.C. Linn, J.A. Foekens, S. Sleijfer, E.M. Berns, M.P. Jansen, Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen, Breast Cancer Res Treat, 139 (2013) 39-49.[71] A. Brodie, L. Macedo, G. Sabnis, Aromatase resistance mechanisms in model systems in vivo, J Steroid Biochem Mol Biol, 118 (2010) 283-287.[72] S. Masri, S. Phung, X. Wang, X. Wu, Y.C. Yuan, L. Wagman, S. Chen, Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor, Cancer Res, 68 (2008) 4910-4918.[73] T. Nishimura, K. Nakamura, S. Yamashita, S. Ikeda, K. Kigure, T. Minegishi, Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor, BMC Cancer, 15 (2015) 957.
[2] W.R. Miller, Aromatase inhibitors: prediction of response and nature of resistance, Expert Opin Pharmacother, 11 (2010) 1873-1887.
[3] P.E. Lonning, H.P. Eikesdal, Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved, Endocr Relat Cancer, 20 (2013) R183-201.
[4] M. Dowsett, C. Allred, J. Knox, E. Quinn, J. Salter, C. Wale, J. Cuzick, J. Houghton, N. Williams, E. Mallon, H. Bishop, I. Ellis, D. Larsimont, H. Sasano, P. Carder, A.L. Cussac, F. Knox, V. Speirs, J. Forbes, A. Buzdar, Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial, J Clin Oncol, 26 (2008) 1059-1065.
[5] M. Dowsett, J. Houghton, C. Iden, J. Salter, J. Farndon, R. A'Hern, R. Sainsbury, M. Baum, Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status, Ann Oncol, 17 (2006) 818-826.
[6] S.J. Houston, T.A. Plunkett, D.M. Barnes, P. Smith, R.D. Rubens, D.W. Miles, Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer, Brit J Cancer, 79 (1999) 1220-1226.
[7] B.B. Rasmussen, M.M. Regan, A.E. Lykkesfeldt, P. Dell'Orto, B. Del Curto, K.L. Henriksen, M.G. Mastropasqua, K.N. Price, E. Mery, M. Lacroix-Triki, S. Braye, H.J. Altermatt, R.D. Gelber, M. Castiglione-Gertsch, A. Goldhirsch, B.A. Gusterson, B. Thurlimann, A.S. Coates, G. Viale, B.I.G. Collaborative, G. International Breast Cancer Study, Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial, Lancet Oncol, 9 (2008) 23-28.
[8] S. Hole, A.M. Pedersen, S.K. Hansen, J. Lundqvist, C.W. Yde, A.E. Lykkesfeldt, New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane, Int J Oncol, 46 (2015) 1481-1490.
[9] S.L. Tilghman, I. Townley, Q. Zhong, P.P. Carriere, J. Zou, S.D. Llopis, L.C. Preyan, C.C. Williams, E. Skripnikova, M.R. Bratton, Q. Zhang, G. Wang, Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness, Mol Cell Proteomics, 12 (2013) 2440-2455.
[10] L.A. Martin, I. Farmer, S.R. Johnston, S. Ali, C. Marshall, M. Dowsett, Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation, J Biol Chem, 278 (2003) 30458-30468.
[11] H. Aguilar, X. Sole, N. Bonifaci, J. Serra-Musach, A. Islam, N. Lopez-Bigas, M. Mendez-Pertuz, R.L. Beijersbergen, C. Lazaro, A. Urruticoechea, M.A. Pujana, Biological reprogramming in acquired resistance to endocrine therapy of breast cancer, Oncogene, 29 (2010) 6071-6083.
[12] D. Jelovac, G. Sabnis, B.J. Long, L. Macedo, O.G. Goloubeva, A.M. Brodie, Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole, Cancer Res, 65 (2005) 5380-5389.
[13] G. Sabnis, O. Goloubeva, R. Gilani, L. Macedo, A. Brodie, Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment, Molecular cancer therapeutics, 9 (2010) 46-56.
[14] A. Brodie, D. Jelovac, L. Macedo, G. Sabnis, S. Tilghman, O. Goloubeva, Therapeutic observations in MCF-7 aromatase xenografts, Clin Cancer Res, 11 (2005) 884s-888s.
[15] L.A. Martin, I. Farmer, S.R. Johnston, S. Ali, M. Dowsett, Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation, Endocr Relat Cancer, 12 Suppl 1 (2005) S75-84.
[16] T.W. Miller, B.T. Hennessy, A.M. Gonzalez-Angulo, E.M. Fox, G.B. Mills, H. Chen, C. Higham, C. Garcia-Echeverria, Y. Shyr, C.L. Arteaga, Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer, J Clin Invest, 120 (2010) 2406-2413.
[17] G.J. Sabnis, D. Jelovac, B. Long, A. Brodie, The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation, Cancer Res, 65 (2005) 3903-3910.
[18] G. Sabnis, A. Brodie, Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance, Mol Cell Endocrinol, 340 (2011) 142-147.
[19] W. Yue, P. Fan, J. Wang, Y. Li, R.J. Santen, Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells, J Steroid Biochem Mol Biol, 106 (2007) 102-110.
[20] S. Masri, S. Phung, X. Wang, S. Chen, Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines, J Steroid Biochem Mol Biol, 118 (2010) 277-282.
[21] M.A. Olayioye, R.M. Neve, H.A. Lane, N.E. Hynes, The ErbB signaling network: receptor heterodimerization in development and cancer, EMBO J, 19 (2000) 3159-3167.
[22] Y. Yarden, M.X. Sliwkowski, Untangling the ErbB signalling network, Nat Rev Mol Cell Biol, 2 (2001) 127-137.
[23] D. Graus-Porta, R.R. Beerli, J.M. Daly, N.E. Hynes, ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling, EMBO J, 16 (1997) 1647-1655.
[24] T. Holbro, R.R. Beerli, F. Maurer, M. Koziczak, C.F. Barbas, 3rd, N.E. Hynes, The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation, Proc Natl Acad Sci U S A, 100 (2003) 8933-8938.
[25] J. Baselga, V. Semiglazov, P. van Dam, A. Manikhas, M. Bellet, J. Mayordomo, M. Campone, E. Kubista, R. Greil, G. Bianchi, J. Steinseifer, B. Molloy, E. Tokaji, H. Gardner, P. Phillips, M. Stumm, H.A. Lane, J.M. Dixon, W. Jonat, H.S. Rugo, Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer, J Clin Oncol, 27 (2009) 2630-2637.
[26] B. Kaufman, J.R. Mackey, M.R. Clemens, P.P. Bapsy, A. Vaid, A. Wardley, S. Tjulandin, M. Jahn, M. Lehle, A. Feyereislova, C. Revil, A. Jones, Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study, J Clin Oncol, 27 (2009) 5529-5537.
[27] J. Geisler, S. Detre, H. Berntsen, L. Ottestad, B. Lindtjorn, M. Dowsett, P. Einstein Lonning, Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer, Clin Cancer Res, 7 (2001) 1230-1236.
[28] J. Geisler, H. Helle, D. Ekse, N.K. Duong, D.B. Evans, Y. Nordbo, T. Aas, P.E. Lonning, Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels, Clin Cancer Res, 14 (2008) 6330-6335.
[29] W.R. Miller, A. Larionov, L. Renshaw, T.J. Anderson, J.R. Walker, A. Krause, T. Sing, D.B. Evans, J.M. Dixon, Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole, J Clin Oncol, 27 (2009) 1382-1387.
[30] J.M. Harvey, G.M. Clark, C.K. Osborne, D.C. Allred, Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer, J Clin Oncol, 17 (1999) 1474-1481.
[31] W.R. Miller, A.A. Larionov, L. Renshaw, T.J. Anderson, S. White, J. Murray, E. Murray, G. Hampton, J.R. Walker, S. Ho, A. Krause, D.B. Evans, J.M. Dixon, Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole, Pharmacogenet Genomics, 17 (2007) 813-826.
[32] S.A. Moestue, C.G. Dam, S.S. Gorad, A. Kristian, A. Bofin, G.M. Maelandsmo, O. Engebraten, I.S. Gribbestad, G. Bjorkoy, Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer, Breast Cancer Res, 15 (2013) R16.
[33] M.H. Flageng, S. Knappskog, B.P. Haynes, P.E. Lonning, G. Mellgren, Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue, PloS one, 8 (2013) e74618.
[34] J. Geisler, B. Haynes, G. Anker, M. Dowsett, P.E. Lonning, Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study, J Clin Oncol, 20 (2002) 751-757.
[35] J. Geisler, N. King, M. Dowsett, L. Ottestad, S. Lundgren, P. Walton, P.O. Kormeset, P.E. Lonning, Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer, Br J Cancer, 74 (1996) 1286-1291.
[36] J. Geisler, N. King, G. Anker, G. Ornati, E. Di Salle, P.E. Lonning, M. Dowsett, In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients, Clin Cancer Res, 4 (1998) 2089-2093.
[37] R.I. Yarden, M.A. Wilson, S.A. Chrysogelos, Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth, J Cell Biochem Suppl, Suppl 36 (2001) 232-246.
[38] M.A. Wilson, S.A. Chrysogelos, Identification and characterization of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone-dependent breast cancer cells, Journal of cellular biochemistry, 85 (2002) 601-614.
[39] J.M. Gee, M.E. Harper, I.R. Hutcheson, T.A. Madden, D. Barrow, J.M. Knowlden, R.A. McClelland, N. Jordan, A.E. Wakeling, R.I. Nicholson, The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro, Endocrinology, 144 (2003) 5105-5117.
[40] T.W. Miller, J.M. Balko, C.L. Arteaga, Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer, J Clin Oncol, 29 (2011) 4452-4461.
[41] T. van Agthoven, A.M. Sieuwerts, D. Meijer, M.E. Meijer-van Gelder, T.L. van Agthoven, R. Sarwari, S. Sleijfer, J.A. Foekens, L.C. Dorssers, Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response, Endocr Relat Cancer, 17 (2010) 215-230.
[42] W.R. Miller, A. Larionov, T.J. Anderson, D.B. Evans, J.M. Dixon, Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole, Pharmacogenomics J, 12 (2012) 10-21.
[43] L.R. Yates, M. Gerstung, S. Knappskog, C. Desmedt, G. Gundem, P. Van Loo, T. Aas, L.B. Alexandrov, D. Larsimont, H. Davies, Y. Li, Y.S. Ju, M. Ramakrishna, H.K. Haugland, P.K. Lilleng, S. Nik-Zainal, S. McLaren, A. Butler, S. Martin, D. Glodzik, A. Menzies, K. Raine, J. Hinton, D. Jones, L.J. Mudie, B. Jiang, D. Vincent, A. Greene-Colozzi, P.Y. Adnet, A. Fatima, M. Maetens, M. Ignatiadis, M.R. Stratton, C. Sotiriou, A.L. Richardson, P.E. Lonning, D.C. Wedge, P.J. Campbell, Subclonal diversification of primary breast cancer revealed by multiregion sequencing, Nat Med, 21 (2015) 751-759.
[44] A. Mackay, A. Urruticoechea, J.M. Dixon, T. Dexter, K. Fenwick, A. Ashworth, S. Drury, A. Larionov, O. Young, S. White, W.R. Miller, D.B. Evans, M. Dowsett, Molecular response to aromatase inhibitor treatment in primary breast cancer, Breast Cancer Res, 9 (2007) R37.
[45] M. De Laurentiis, G. Arpino, E. Massarelli, A. Ruggiero, C. Carlomagno, F. Ciardiello, G. Tortora, D. D'Agostino, F. Caputo, G. Cancello, E. Montagna, L. Malorni, L. Zinno, R. Lauria, A.R. Bianco, S. De Placido, A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer, Clin Cancer Res, 11 (2005) 4741-4748.
[46] G. Arpino, L. Wiechmann, C.K. Osborne, R. Schiff, Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance, Endocr Rev, 29 (2008) 217-233.
[47] M.J. Ellis, Y. Tao, O. Young, S. White, A.D. Proia, J. Murray, L. Renshaw, D. Faratian, J. Thomas, M. Dowsett, A. Krause, D.B. Evans, W.R. Miller, J.M. Dixon, Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole, J Clin Oncol, 24 (2006) 3019-3025.
[48] G. Konecny, G. Pauletti, M. Pegram, M. Untch, S. Dandekar, Z. Aguilar, C. Wilson, H.M. Rong, I. Bauerfeind, M. Felber, H.J. Wang, M. Beryt, R. Seshadri, H. Hepp, D.J. Slamon, Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer, J Natl Cancer Inst, 95 (2003) 142-153.
[49] I. Pinhel, M. Hills, S. Drury, J. Salter, G. Sumo, R. A'Hern, J.M. Bliss, I. Sestak, J. Cuzick, P. Barrett-Lee, A. Harris, M. Dowsett, N.A.B.C.T.M. Group, ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer, Breast Cancer Res, 14 (2012) R46.
[50] A. Agrawal, J.F. Robertson, K.L. Cheung, E. Gutteridge, I.O. Ellis, R.I. Nicholson, J.M. Gee, Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies, Int J Cancer, 138 (2016) 146-159.
[51] K. Sonne-Hansen, I.C. Norrie, K.B. Emdal, R.V. Benjaminsen, T. Frogne, I.J. Christiansen, T. Kirkegaard, A.E. Lykkesfeldt, Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance, Breast Cancer Res Treat, 121 (2010) 601-613.
[52] M. Moerkens, Y. Zhang, L. Wester, B. van de Water, J.H. Meerman, Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor alpha signalling and results in tamoxifen insensitive proliferation, BMC Cancer, 14 (2014) 283.
[53] G. Sabnis, O. Goloubeva, D. Jelovac, A. Schayowitz, A. Brodie, Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens, Clin Cancer Res, 13 (2007) 2751-2757.
[54] G. Sabnis, A. Schayowitz, O. Goloubeva, L. Macedo, A. Brodie, Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen, Cancer Res, 69 (2009) 1416-1428.
[55] G.J. Sabnis, A. Kazi, O. Golubeva, P. Shah, A. Brodie, Effect of selumetinib on the growth of anastrozole-resistant tumors, Breast Cancer Res Treat, 138 (2013) 699-708.
[56] S. Johnston, J. Pippen, Jr., X. Pivot, M. Lichinitser, S. Sadeghi, V. Dieras, H.L. Gomez, G. Romieu, A. Manikhas, M.J. Kennedy, M.F. Press, J. Maltzman, A. Florance, L. O'Rourke, C. Oliva, S. Stein, M. Pegram, Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer, J Clin Oncol, 27 (2009) 5538-5546.
[57] R.S. Finn, M.F. Press, J. Dering, L. O'Rourke, A. Florance, C. Ellis, A.M. Martin, S. Johnston, Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer, Clin Cancer Res, 20 (2014) 736-743.
[58] K. Tryfonidis, G. Basaran, J. Bogaerts, M. Debled, L. Dirix, J.C. Thery, V.C. Tjan-Heijnen, D. Van den Weyngaert, T. Cufer, M. Piccart, D. Cameron, E.O.-B.C. Group, A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378), Eur J Cancer, 53 (2016) 144-154.
[59] R.W. Carlson, A. O'Neill, T. Vidaurre, H.L. Gomez, S.S. Badve, G.W. Sledge, A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer, Breast Cancer Res Treat, 133 (2012) 1049-1056.
[60] B. Manavathi, O. Dey, V.N. Gajulapalli, R.S. Bhatia, S. Bugide, R. Kumar, Derailed estrogen signaling and breast cancer: an authentic couple, Endocr Rev, 34 (2013) 1-32.
[61] E.J. Filardo, P. Thomas, Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology, Endocrinology, 153 (2012) 2953-2962.
[62] E.J. Filardo, J.A. Quinn, A.R. Frackelton, Jr., K.I. Bland, Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis, Mol Endocrinol, 16 (2002) 70-84.
[63] R. Lappano, P. De Marco, E.M. De Francesco, A. Chimento, V. Pezzi, M. Maggiolini, Cross-talk between GPER and growth factor signaling, J Steroid Biochem Mol Biol, 137 (2013) 50-56.
[64] E.R. Prossnitz, M. Barton, The G-protein-coupled estrogen receptor GPER in health and disease, Nat Rev Endocrinol, 7 (2011) 715-726.
[65] Z. Mo, M. Liu, F. Yang, H. Luo, Z. Li, G. Tu, G. Yang, GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer, Breast Cancer Res, 15 (2013) R114.
[66] S.R. Johnston, Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer, Clin Cancer Res, 12 (2006) 1061s-1068s.
[67] J. Baselga, J. Cortes, S.B. Kim, S.A. Im, R. Hegg, Y.H. Im, L. Roman, J.L. Pedrini, T. Pienkowski, A. Knott, E. Clark, M.C. Benyunes, G. Ross, S.M. Swain, C.S. Group, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, N Engl J Med, 366 (2012) 109-119.
[68] S. Di Cosimo, J. Baselga, Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation?, Clin Cancer Res, 15 (2009) 5017-5019.
[69] S. Loi, B. Haibe-Kains, S. Majjaj, F. Lallemand, V. Durbecq, D. Larsimont, A.M. Gonzalez-Angulo, L. Pusztai, W.F. Symmans, A. Bardelli, P. Ellis, A.N. Tutt, C.E. Gillett, B.T. Hennessy, G.B. Mills, W.A. Phillips, M.J. Piccart, T.P. Speed, G.A. McArthur, C. Sotiriou, PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer, Proc Natl Acad Sci U S A, 107 (2010) 10208-10213.
[70] D.E. Ramirez-Ardila, J.C. Helmijr, M.P. Look, I. Lurkin, K. Ruigrok-Ritstier, S. van Laere, L. Dirix, F.C. Sweep, P.N. Span, S.C. Linn, J.A. Foekens, S. Sleijfer, E.M. Berns, M.P. Jansen, Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen, Breast Cancer Res Treat, 139 (2013) 39-49.
[71] A. Brodie, L. Macedo, G. Sabnis, Aromatase resistance mechanisms in model systems in vivo, J Steroid Biochem Mol Biol, 118 (2010) 283-287.
[72] S. Masri, S. Phung, X. Wang, X. Wu, Y.C. Yuan, L. Wagman, S. Chen, Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor, Cancer Res, 68 (2008) 4910-4918.
[73] T. Nishimura, K. Nakamura, S. Yamashita, S. Ikeda, K. Kigure, T. Minegishi, Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor, BMC Cancer, 15 (2015) 957.






Gene	Primer sequences	UPL probea  
EGFR/HER-1	Left: 5'-cagccacccatatgtaccatc-3'Right: 5'-aactttgggcgactatctgc-3'	42
HER-2/neu	Left: 5'-ccctgacctgctggaaaag-3'Right: 5'-ggccgacattcagagtcaat-3'	43
HER-3	Left: 5'-acagccccagatctgcac-3'Right: 5'-gttgggcgaatgttctcatc-3'	9
HER-4	Left: 5'-ttccactttaccacaacatgcta-3'Right: 5'-cagaatgaagagcccacca-3'	78
NRG1	Left: 5'-gatcagcaaattaggaaatgacag-3'Right: 5'-ggcataccagtgatgatctcg-3'	53
Supplementary Table 1. Primer sequences and UPL probe number







aUniversal probe library (UPL) probe number (Roche, Basel, Switzerland)



Supplementary Table 2. Breast tumors with HER-receptor mRNA levels above detection limit
	EGFR/HER-1	HER-2/neu	HER-3	HER-4	NRG1
Pre-treatment	82/85 	82/85 	81/85	84/85	78/85
2 weeks	62/64 	60/64	62/64	62/64	53/64
3 months	82/85	81/85	82/85	80/85	79/85
Total	226/234 (96.6%)	223/234 (95.3%)	225/234 (96.2%)	226/234 (96.6%)	210/234 (89.7%)






Supplementary Table 3. PIK3CA mutations and pAKT activation related to response to treatment and changes in HER-1-4 and NRG1 in the (B) data set.

		Mutations	Proteina	Change in mRNA levelsb
C	Response	Akt1 E17K	PI3CAE542K	PI3CA H1047R	PI3CA M1043I	pAkt	EGFR/HER-1	HER-2/neu	HER-3	HER-4	NRG1
1	NR		X			NA	4.2	0.98	0.81	2.1	6.2
2	NR					NA	0.59	0.34	0.03	0.02	0.15
3	NR	X				NA	34.4	0.35	0.22	0.19	188
4	NR					↑	0.72	25.4	0.67	0.21	0.23
5	NR		X			NA	0.83	1.5	0.58	0.73	0.29
6	R			X		↑	0.87	1.4	1.1	4.6	0.28
7	R			X		NA	0.59	1.7	1.5	1.5	1.0
8	R			X		NA	1.9	1.1	0.98	0.6	22
9	R			X		NA	2.5	0.73	0.46	0.71	3.6
10	R					-	0.80	ND	0.04	ND	ND
11	R		X		X	↓	1.2	1.2	1.1	1.2	2.1
12	R					↑	1.3	1.1	0.69	0.46	2.35
13	R			X		↓	2.68	0.76	0.9	10.1	1.7
14	R					NA	2.2	1.2	1.2	1.2	0.73
15	R			X		↓	4.2	0.65	0.26	0.7	5.2
16	R					↑	0.05	10.3	135	73.3	0.41
17	R		X			NA	6.9	1.0	0.88	0.88	9.9
18	R		X			↓	0.67	2.6	6.6	60.4	1.0
19	R					↓	4.9	0.68	0.35	0.17	35.9
20	R			X		NA	ND	5.2	ND	ND	7.6
21	R					NA	1.1	0.52	0.53	0.46	0.32
a Increased (↑) or decreased (↓) signal intensity during AI treatment
b Fold changes in mRNA levels during three months on AI treatment 
R; responders, NR; non responders, NA; not analyzed, ND, not detected (in either pre or post treatment sample or both)
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